- |||||||||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Analysis of Deficiency of Adenosine Deaminase 2 Pathogenesis Based on Single Cell RNA Sequencing of Monocytes (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_3470; P=N/A Overall, each monocyte subtype of DADA2 patients showed upregulation of immune response gene sets compared to controls. DADA2 patients have increased numbers of nonclassical monocytes which may contribute the immune dysregulation and increased inflammation observed in the disease.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion date, Trial primary completion date, HEOR, Compliance, Patient reported outcomes: Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service (clinicaltrials.gov) - Nov 7, 2019 P=N/A, N=116, Completed, DADA2 patients have increased numbers of nonclassical monocytes which may contribute the immune dysregulation and increased inflammation observed in the disease. Trial completion date: Nov 2018 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Systemic biological treatment in ophthalmology (Pubmed Central) - Nov 3, 2019 In all cases, emerging new, biological therapy (adalimumab) was necessary to achieve permanent inactive period of uveitis and the autoimmune disease...Orv Hetil. 2019; 160(44): 1744-1750.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Trial completion date: TURA: Targeted Ultrasound in Rheumatoid Arthritis (clinicaltrials.gov) - Nov 1, 2019 P4, N=183, Completed, This real-world study with pragmatic drug level sampling provides evidence to support the proactive measurement of adalimumab levels in psoriasis to direct treatment strategy, and is relevant to other inflammatory diseases. Active, not recruiting --> Completed | N=400 --> 183 | Trial completion date: Dec 2018 --> Jul 2019
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Recall Urticaria in Adalimumab Hypersensitivity. (Pubmed Central) - Oct 30, 2019 Our findings highlight the need for a RA national registry to improve the quality of care of these patients in UAE. No abstract available
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal, HEOR, Monotherapy: Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. (Pubmed Central) - Oct 29, 2019 Concomitant methotrexate, leflunomide and csDMARDs combination associate with longer survival on bDMARD. Our data confirm the effectiveness of the current practices in the choice of etanercept as first-line anti-TNF monotherapy and strengthen the currently recommended use of bDMARDs in combination with csDMARDs.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab in Psoriasis: How Much Is Enough? (Pubmed Central) - Oct 28, 2019 Wilkinson et al. explore these questions in a real-world psoriasis cohort on adalimumab monotherapy, defining a therapeutic range and finding value in early measurement for predicting clinical response.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Pricing, Reimbursement: As I understand it the biologics like Humira, Enbrel, and remicade cost a lot of money to manufacture. And Medicade does not cover those. A lot of the new biologics are close to $60,000 a year without insurance. Crazy (Twitter) - Oct 27, 2019
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal: TNF inhibitors for psoriasis. (Pubmed Central) - Oct 25, 2019 An understanding of these idiosyncrasies can help guide therapeutic decisions for patients with psoriasis that also have inflammatory bowel disease, hepatitis C, hepatitis B, latent tuberculosis, obesity, cardiovascular disease, and heart failure. It can also help when selecting the right treatment for pregnant patients, children and adolescents, or those with insurance constraints or compliance issues.
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Targeted therapies for pediatric psoriasis. (Pubmed Central) - Oct 25, 2019 In Europe, adalimumab is also approved for pediatric psoriasis for 4 years of age and older. While biologics have the advantage of less frequent administration, greater and more rapid efficacy than methotrexate, fewer side effects, and a less rigorous need for monitoring, their cost is much higher than that of methotrexate and other systemic medications, concerns about the development of neutralizing antibodies necessitate continuous treatment, and their long-term safety profile remains to be determined.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. (Pubmed Central) - Oct 25, 2019 Although many treatments have been tried and tested to date, there is only one Food and Drug Administration-approved treatment option, adalimumab, which is currently indicated for moderateto- severe HS...In this article, we summarize the existing data on biologics and other small-molecule systemic agents, as well as share our personal experiences with the pharmacological management of HS in the clinical setting. Continued challenges that limit our ability to study and treat this disease effectively include a lack of a universally employed scoring system for disease severity, high variability in clinical presentation, high cost of off-label therapy, and the scarcity of long-term studies on treatment response and medication safety.
- |||||||||| Orencia (abatacept) / BMS, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
A SUCCESSFUL TREATMENT WITH ABATACEPT IN STEROID RESISTANT FOCAL SEGMENTAL GLOMERULOSCLEROSIS () - Oct 25, 2019 - Abstract #IPNA2019IPNA_20; Herein we present our experience with abatacept, a cytotoxic Tlymphocyte-associated antigen 4-immunoglobulin fusion protein (CTLA-4-Ig), in a patient diagnosed with primary FSGS and resistant to steroid, cyclosporine A (CsA), Mycofenolat mophetinile (MMF) and rituximab...After administration of abatacept, proteinuria level decreased below 1 gram/day and serum albumin levels increased to 3 mg/dL. This case indicates that abatacept can be at least partially effective in FSGS with resistance to other immunsupressive therapies such as CsA, cyclophosphamide, MMF and rituximab.
- |||||||||| Clinical, Journal: The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis. (Pubmed Central) - Oct 24, 2019
The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory drivers and restore the Th17/Treg balance in psoriasis. Our data suggest that female sex was associated with a lower rate of response to treatment and of disease remission in patients with axSpA treated with antitumor necrosis factor-α drugs.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline. (Pubmed Central) - Oct 24, 2019 As target protein, both homodimer and homotrimer forms of TNFα were considered. The screening results showed that indinavir and medroxalol from NPC chemical library and a set of compounds (AT-057/43115940, AP-970/42897107, AK-968/41925665, AI-204/31679053, AN-648/41666950, AN-698/42006940) from Specs-SC database were identified as safe and active direct inhibitors of TNFα.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Biomarker, Journal: Histone modifications associated with biological drug response in moderate-to-severe psoriasis. (Pubmed Central) - Oct 24, 2019 In patients without PsA significant changes in methylated H3K4 were found between responders and non-responders to biological drugs at 3 and 6 months. Although further studies should confirm these results, these findings suggest that H3K27 and H3K4 methylation may contribute to patients' response to biological drugs in psoriasis.
|